期刊文献+

他汀类药物防治帕金森病的临床效果及作用机制研究进展 被引量:2

Efficacy and mechanism of statins in prevention and treatment of Parkinson disease: recent progress
下载PDF
导出
摘要 他汀类药物是一类降血脂药,它们是羟甲基戊二酸单酰辅酶A还原酶的抑制剂。他汀类药物具有多效性,最近的研究表明其可能具有防治帕金森病的潜力。本文就近年来他汀类药物在防治帕金森病的临床效果及作用机制方面的研究进展作一综述。 Statins are a class of hypolipidemic drugs,and they are HMG-CoA reductase inhibitors.Statins are pleiotropic;recent studies have suggested that they might have a potential for prevention and treatment of Parkinson disease.This paper reviews recent researches about the roles of statins in the prevention and therapy of Parkinson disease in the nearest few years.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2011年第1期92-95,共4页 Academic Journal of Second Military Medical University
关键词 他汀类药物 帕金森病 预防 治疗 statins Parkinson disease prevention therapy
  • 相关文献

参考文献34

  • 1Anonymous. Choice of lipid-lowering drug[J]. Med Lett Drug Ther,1998,40:117-122.
  • 2Rascol O, Payoux P, Ory F, Ferreira J J, Brefel-Courbon C, Montastruc J L. Limitations of current Parkinson' s disease therapy[J]. Ann Neurol,2003,53(Suppl 3)S3 -S15.
  • 3Wolozin B,Wang S W,Li N C,Lee A,I.ee T A,Kazis L E. Simvastatin is associated with a reduced incidence of dementia and Parkinson' s disease[J]. BMC Med, 2007,5 : 20.
  • 4Wahner A D,Bronstein J M,Bordelon Y M,Ritz B. Statin use and the risk of Parkinson disease[J]. Neurology, 2008,70 ( 16 Pt 2) :1418-1422.
  • 5Mutez E, Duhamel A, Defebvre L, Border R, Destee A, Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson' s disease[J].Pharmacol Res, 2009, 60,41- 45.
  • 6Samii A,Carleton B C,Etminan M. Statin use and the risk of Parkinson disease: a nested case control study[J]. J Clin Neu rosci,2008,]5 : 1272- 1273.
  • 7Murphy D D, Rueter S M, Trojanowski J Q, Lee V M. Synucle ins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons[J]. J Neurosci,2000,20.3214- 3220.
  • 8Beyer K,Ariza A. Protein aggregation mechanisms in synuclei nopathies: comrnonalities and differences[J]. J Neuropathol Exp Neurol,2007,66:965 -974.
  • 9Senior S L, Ninkina N, Deacon R, Bannerman D, Buchman V L, Cragg S J,et al. Increased striatal dopamine release and hyperdopamineic-like bahaviour in mice lacking both alpha-synuclein and gamma-synuclein[J]. Eur J Neurosci, 2008,27 : 947-957.
  • 10Liao P C,Kuo Y M,Hsu H C,Cherng C G,Yu L. Local proteins associated with meihamphetamine-induced nigrostriatal dopam inergic neurotoxicity[J]. J Neurochern, 2005,95 : 160-168.

同被引文献60

引证文献2

二级引证文献72

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部